SecBot SecBot
SECBOTREPLAY Home › Report › DRTS

DRTS · Alpha Tau announced the successful treatment of the first patient in…

Alpha Tau Medical Ltd. · 6-K filed Jul 15, 2026 at 08:30 ET

At the news

BULLISHIMPACT 5/10

6-K filed Jul 15, 2026 at 08:30 ET

Alpha Tau announced the successful treatment of the first patient in its ADMIRE study, evaluating Alpha DaRT for immunocompromised patients with recurrent cutaneous squamous cell carcinoma (cSCC). The study targets a high-need population with limited treatment options and builds on momentum from the recently completed ReSTART pivotal trial. This is an early clinical milestone with no efficacy data reported.

  • First patient treated in ADMIRE study at Banner MD Anderson Cancer Center
  • ADMIRE is a prospective, single-arm study enrolling up to 28 immunocompromised patients with recurrent cSCC
  • Primary endpoint: objective response rate (ORR) per RECIST v1.1; secondary endpoints include PFS, OS, and local control over 12 months
  • ReSTART pivotal trial for recurrent cSCC recently completed patient enrollment

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access